Journal · Updated 2026-08-11
Medi-Cal and GLP-1s in 2026: What California Actually Cut on January 1, and Every Door Still Open
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Effective January 1, 2026, Medi-Cal — California's Medicaid program, the country's largest — stopped covering GLP-1 medications prescribed for weight loss or weight-related indications for members twenty-one and older. Per the Medi-Cal Rx provider bulletins, Wegovy, Zepbound, and Saxenda were removed from the Contract Drug List for those uses and claims now deny. What did not end, in DHCS's own words: coverage for FDA-approved indications other than weight loss — type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease among them — with the appropriate ICD-10 diagnosis code, utilization controls, and prior authorization. Members under twenty-one keep an individualized medical-necessity path under the federal EPSDT benefit. This page records the change with its sources, then maps every door that remains.
What the bulletins actually say
The primary sources are unambiguous and public. Medi-Cal Rx's provider notice (October 2025, on the DHCS Medi-Cal Rx site) announced that GLP-1s would no longer be a covered benefit when used for weight loss, advised prescribers to consider transitioning members to other therapies or weaning on a case-by-case, individualized plan, and confirmed continued coverage for FDA-approved non-weight indications subject to diagnosis codes, utilization controls, and PA. Plan-level implementation notices (for example, IEHP's December 2025 provider notice) specified the mechanics: Wegovy, Zepbound, and Saxenda off the CDL for weight-loss indications effective January 1, 2026, with claims denying, and PA requests for members under twenty-one reviewed for medical necessity under EPSDT. The California Medical Association's coverage of the change and subsequent reporting (Spectrum News, February 2026) added the context: Medi-Cal had covered weight-loss medications since 2006, and the state framed the cut as a response to surging costs. Those are the facts of record; the rest of this page is what to do inside them.
The doors that remain open in California
Because the exclusion is indication-based, the indication doors apply with full force. A Medi-Cal member with type 2 diabetes remains in ordinary covered territory for Ozempic or Mounjaro with the diagnosis code and PA. A member with established cardiovascular disease plus overweight or obesity can be evaluated for Wegovy under its cardiovascular-risk indication — DHCS's own bulletin names atherosclerotic cardiovascular disease among the covered uses. A member with diabetes and chronic kidney disease maps to Ozempic's kidney indication, also named in the bulletin's covered-indications language. Each door requires the diagnosis to be real and documented, runs through prior authorization, and is a conversation to have with the prescriber holding your chart — the PA guide and appeal guide apply wholesale, and members denied coverage can appeal through DHCS's processes. For members under twenty-one, EPSDT's individualized medical-necessity review is its own lane, run through the PA process rather than the adult exclusion.
If every door is closed: the honest cash map
For the Medi-Cal member with obesity and none of the covered comorbidities, January 2026 converted a covered benefit into a cash decision — landing hardest on exactly the budgets least able to absorb it. The honest figures, from this site's computed database: manufacturer channels sell FDA-approved product at prices that have fallen but remain heavy for a Medicaid-eligible budget (brand tirzepatide vials in the three-to-four-fifty range monthly; the approved oral semaglutide tablet's introductory tier near one-fifty), while the verified compounded floor runs roughly one-thirty to one-eighty a month with the standard homework — the fifteen-minute verification — attached, and manufacturer savings cards are generally unavailable to Medicaid enrollees for covered products. One number to keep on paper before any cash decision: Medi-Cal Rx Customer Service, 1-800-977-2273, staffed around the clock — the definitive answer on whether your diagnosis, today, opens a door this page couldn't see from here. Coverage rules change through budget cycles; this record carries its capture date, and the 2026 change ledger logs each move as it lands.
Questions people ask
Does Medi-Cal cover Wegovy or Zepbound for weight loss in 2026?
No — effective January 1, 2026, Medi-Cal ended GLP-1 coverage for weight loss and weight-related indications for members 21 and older; Wegovy, Zepbound, and Saxenda came off the Contract Drug List for those uses and claims deny. Coverage continues for FDA-approved non-weight indications with diagnosis codes and prior authorization.
What GLP-1 uses does Medi-Cal still cover?
Per the DHCS Medi-Cal Rx bulletins: FDA-approved indications other than weight loss — type 2 diabetes, atherosclerotic cardiovascular disease, and chronic kidney disease among them — subject to ICD-10 diagnosis codes, utilization controls, and PA. Members under 21 have an individualized medical-necessity path under EPSDT.
Can I appeal a Medi-Cal GLP-1 denial?
Yes — denied members can appeal through the Department of Health Care Services' processes, and the strongest appeals are built to a covered indication's own criteria with documentation. Medi-Cal Rx Customer Service (1-800-977-2273, 24/7) is the definitive first call on what your diagnosis qualifies for.
Why did California stop covering GLP-1s for weight loss?
Cost. Medi-Cal had covered weight-loss medications since 2006, and state officials framed the January 2026 change as a response to surging GLP-1 spending amid broader Medicaid budget pressure — a rationale reported by the California Medical Association and California news coverage of the cut.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.